✦ LIBER ✦

Phase I and pharmacokinetic study of XR11576, an oral topoisomerase I and II inhibitor, administered on days 1–5 of a 3-weekly cycle in patients with advanced solid tumours

✍ Scribed by de Jonge, M J A; Kaye, S; Verweij, J; Brock, C; Reade, S; Scurr, M; van Doorn, L; Verheij, C; Loos, W; Brindley, C; Mistry, P; Cooper, M; Judson, I

Book ID: 109998283
Publisher: Nature Publishing Group
Year: 2004
Tongue: English
Weight: 127 KB
Volume: 91
Category: Article
ISSN: 0007-0920
DOI: 10.1038/sj.bjc.6602178

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase I clinical, pharmacokinetic and ph

Phase I clinical, pharmacokinetic and pharmacodynamic study of SB939, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumours

✍ Razak, A R A; Hotte, S J; Siu, L L; Chen, E X; Hirte, H W; Powers, J; Walsh, W; 📂 Article 📅 2011 🏛 Nature Publishing Group 🌐 English ⚖ 308 KB

A phase I dose escalation study of the p

A phase I dose escalation study of the pharmacokinetics and tolerability of ZK 304709, an oral multi-targeted growth inhibitor (MTGI™), in patients with advanced solid tumours

✍ Edwina N. Scott; Anne L. Thomas; L. Rhoda Molife; Samreen Ahmed; Sarah Blagden; 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 253 KB

A Phase I study to assess the safety, to

A Phase I study to assess the safety, tolerability, and pharmacokinetics of AZD4877, an intravenous Eg5 inhibitor in patients with advanced solid tumors

✍ J. R. Infante; R. Kurzrock; J. Spratlin; H. A. Burris; S. G. Eckhardt; J. Li; K. 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 338 KB

Phase I study of TZT-1027, a novel synth

Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, which was administered to patients with advanced solid tumors on days 1 and 8 in 3-week courses

✍ Kenji Tamura; Kazuhiko Nakagawa; Takayasu Kurata; Taroh Satoh; Toshiji Nogami; K 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 342 KB

A phase I dose escalation study of BIBW

A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours

✍ Eskens, F A L M; Mom, C H; Planting, A S T; Gietema, J A; Amelsberg, A; Huisman, 📂 Article 📅 2007 🏛 Nature Publishing Group 🌐 English ⚖ 173 KB